BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
See today's BioWorld
Home
» Sopherion's Myocet Licensing Inspires $47M Series B Round
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Sopherion's Myocet Licensing Inspires $47M Series B Round
Sep. 24, 2004
By
Randy Osborne
No Comments
Sopherion Therapeutics Inc. raised $47 million in a Series B venture financing and, at the same time, entered a licensing deal with Zeneus Pharma Ltd. for Myocet, a breast cancer therapy approved in Europe and Canada. (BioWorld Today)
BioWorld